A genome-wide loss-of-function screen identifies SLC26A2 as a novel mediator of TRAIL resistance

Lina Y. Dimberg, Christina G. Towers, Kian Behbakht, Taylor J. Hotz, Jihye Kim, Susan Fosmire, Christopher C. Porter, Aik-Choon Tan, Andrew Thorburn, Heide L. Ford

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

TRAIL is a potent death-inducing ligand that mediates apoptosis through the extrinsic pathway and serves as an important endogenous tumor suppressor mechanism. Because tumor cells are often killed by TRAIL and normal cells are not, drugs that activate the TRAIL pathway have been thought to have potential clinical value. However, to date, most TRAIL-related clinical trials have largely failed due to the tumor cells having intrinsic or acquired resistance to TRAIL-induced apoptosis. Previous studies to identify resistance mechanisms have focused on targeted analysis of the canonical apoptosis pathway and other known regulators of TRAIL receptor signaling. To identify novel mechanisms of TRAIL resistance in an unbiased way, we performed a genome-wide shRNA screen for genes that regulate TRAIL sensitivity in sublines that had been selected for acquired TRAIL resistance. This screen identified previously unknown mediators of TRAIL resistance including angiotensin II receptor 2, Crk-like protein, T-Box Transcription Factor 2, and solute carrier family 26 member 2 (SLC26A2). SLC26A2 downregulates the TRAIL receptors, DR4 and DR5, and this downregulation is associated with resistance to TRAIL. Its expression is high in numerous tumor types compared with normal cells, and in breast cancer, SLC26A2 is associated with a significant decrease in relapse-free survival.

Original languageEnglish
Pages (from-to)382-394
Number of pages13
JournalMolecular Cancer Research
Volume15
Issue number4
DOIs
Publication statusPublished - 2017 Apr 1
Externally publishedYes

Fingerprint

Genome
TNF-Related Apoptosis-Inducing Ligand Receptors
Apoptosis
Proto-Oncogene Proteins c-crk
Neoplasms
Down-Regulation
Angiotensin Receptors
Small Interfering RNA
Transcription Factors
Clinical Trials
Breast Neoplasms
Ligands
Recurrence
Pharmaceutical Preparations
Genes

ASJC Scopus subject areas

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Dimberg, L. Y., Towers, C. G., Behbakht, K., Hotz, T. J., Kim, J., Fosmire, S., ... Ford, H. L. (2017). A genome-wide loss-of-function screen identifies SLC26A2 as a novel mediator of TRAIL resistance. Molecular Cancer Research, 15(4), 382-394. https://doi.org/10.1158/1541-7786.MCR-16-0234

A genome-wide loss-of-function screen identifies SLC26A2 as a novel mediator of TRAIL resistance. / Dimberg, Lina Y.; Towers, Christina G.; Behbakht, Kian; Hotz, Taylor J.; Kim, Jihye; Fosmire, Susan; Porter, Christopher C.; Tan, Aik-Choon; Thorburn, Andrew; Ford, Heide L.

In: Molecular Cancer Research, Vol. 15, No. 4, 01.04.2017, p. 382-394.

Research output: Contribution to journalArticle

Dimberg, LY, Towers, CG, Behbakht, K, Hotz, TJ, Kim, J, Fosmire, S, Porter, CC, Tan, A-C, Thorburn, A & Ford, HL 2017, 'A genome-wide loss-of-function screen identifies SLC26A2 as a novel mediator of TRAIL resistance', Molecular Cancer Research, vol. 15, no. 4, pp. 382-394. https://doi.org/10.1158/1541-7786.MCR-16-0234
Dimberg, Lina Y. ; Towers, Christina G. ; Behbakht, Kian ; Hotz, Taylor J. ; Kim, Jihye ; Fosmire, Susan ; Porter, Christopher C. ; Tan, Aik-Choon ; Thorburn, Andrew ; Ford, Heide L. / A genome-wide loss-of-function screen identifies SLC26A2 as a novel mediator of TRAIL resistance. In: Molecular Cancer Research. 2017 ; Vol. 15, No. 4. pp. 382-394.
@article{78ba53e4156b4ed79637da66f9cd66ea,
title = "A genome-wide loss-of-function screen identifies SLC26A2 as a novel mediator of TRAIL resistance",
abstract = "TRAIL is a potent death-inducing ligand that mediates apoptosis through the extrinsic pathway and serves as an important endogenous tumor suppressor mechanism. Because tumor cells are often killed by TRAIL and normal cells are not, drugs that activate the TRAIL pathway have been thought to have potential clinical value. However, to date, most TRAIL-related clinical trials have largely failed due to the tumor cells having intrinsic or acquired resistance to TRAIL-induced apoptosis. Previous studies to identify resistance mechanisms have focused on targeted analysis of the canonical apoptosis pathway and other known regulators of TRAIL receptor signaling. To identify novel mechanisms of TRAIL resistance in an unbiased way, we performed a genome-wide shRNA screen for genes that regulate TRAIL sensitivity in sublines that had been selected for acquired TRAIL resistance. This screen identified previously unknown mediators of TRAIL resistance including angiotensin II receptor 2, Crk-like protein, T-Box Transcription Factor 2, and solute carrier family 26 member 2 (SLC26A2). SLC26A2 downregulates the TRAIL receptors, DR4 and DR5, and this downregulation is associated with resistance to TRAIL. Its expression is high in numerous tumor types compared with normal cells, and in breast cancer, SLC26A2 is associated with a significant decrease in relapse-free survival.",
author = "Dimberg, {Lina Y.} and Towers, {Christina G.} and Kian Behbakht and Hotz, {Taylor J.} and Jihye Kim and Susan Fosmire and Porter, {Christopher C.} and Aik-Choon Tan and Andrew Thorburn and Ford, {Heide L.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1158/1541-7786.MCR-16-0234",
language = "English",
volume = "15",
pages = "382--394",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - A genome-wide loss-of-function screen identifies SLC26A2 as a novel mediator of TRAIL resistance

AU - Dimberg, Lina Y.

AU - Towers, Christina G.

AU - Behbakht, Kian

AU - Hotz, Taylor J.

AU - Kim, Jihye

AU - Fosmire, Susan

AU - Porter, Christopher C.

AU - Tan, Aik-Choon

AU - Thorburn, Andrew

AU - Ford, Heide L.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - TRAIL is a potent death-inducing ligand that mediates apoptosis through the extrinsic pathway and serves as an important endogenous tumor suppressor mechanism. Because tumor cells are often killed by TRAIL and normal cells are not, drugs that activate the TRAIL pathway have been thought to have potential clinical value. However, to date, most TRAIL-related clinical trials have largely failed due to the tumor cells having intrinsic or acquired resistance to TRAIL-induced apoptosis. Previous studies to identify resistance mechanisms have focused on targeted analysis of the canonical apoptosis pathway and other known regulators of TRAIL receptor signaling. To identify novel mechanisms of TRAIL resistance in an unbiased way, we performed a genome-wide shRNA screen for genes that regulate TRAIL sensitivity in sublines that had been selected for acquired TRAIL resistance. This screen identified previously unknown mediators of TRAIL resistance including angiotensin II receptor 2, Crk-like protein, T-Box Transcription Factor 2, and solute carrier family 26 member 2 (SLC26A2). SLC26A2 downregulates the TRAIL receptors, DR4 and DR5, and this downregulation is associated with resistance to TRAIL. Its expression is high in numerous tumor types compared with normal cells, and in breast cancer, SLC26A2 is associated with a significant decrease in relapse-free survival.

AB - TRAIL is a potent death-inducing ligand that mediates apoptosis through the extrinsic pathway and serves as an important endogenous tumor suppressor mechanism. Because tumor cells are often killed by TRAIL and normal cells are not, drugs that activate the TRAIL pathway have been thought to have potential clinical value. However, to date, most TRAIL-related clinical trials have largely failed due to the tumor cells having intrinsic or acquired resistance to TRAIL-induced apoptosis. Previous studies to identify resistance mechanisms have focused on targeted analysis of the canonical apoptosis pathway and other known regulators of TRAIL receptor signaling. To identify novel mechanisms of TRAIL resistance in an unbiased way, we performed a genome-wide shRNA screen for genes that regulate TRAIL sensitivity in sublines that had been selected for acquired TRAIL resistance. This screen identified previously unknown mediators of TRAIL resistance including angiotensin II receptor 2, Crk-like protein, T-Box Transcription Factor 2, and solute carrier family 26 member 2 (SLC26A2). SLC26A2 downregulates the TRAIL receptors, DR4 and DR5, and this downregulation is associated with resistance to TRAIL. Its expression is high in numerous tumor types compared with normal cells, and in breast cancer, SLC26A2 is associated with a significant decrease in relapse-free survival.

UR - http://www.scopus.com/inward/record.url?scp=85017174195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017174195&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-16-0234

DO - 10.1158/1541-7786.MCR-16-0234

M3 - Article

VL - 15

SP - 382

EP - 394

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 4

ER -